RESERVE
min $100
If you invest, you're betting Lifescient, Inc. will be worth more than $15M in the future.
If your dog or cat needed medication for a month and you were told by the vet that you had two treatment options: You could give them a pill every day, or the vet could give a treatment that would last for a month without your intervention.
Which option would you choose?
Administering medication to your pet can be a daunting task, ranging from challenging to nearly impossible. Finding inventive ways to give your pet their dose can be tough, requiring both time and dedication. Lifescient addresses these challenges through our groundbreaking drug delivery platform.
The company founder, Kamalesh Rao, was part of a team that developed LAIs for use in humans suffering from opioid addiction. Lifescient is applying this technology to veterinary medicine to offer supervision-free medications for pets.
This innovation removes the demands of a dosing schedule and can provide treatment for days, weeks or months at a time. After the course of treatment, the LAI is safely absorbed.
Freedom from daily dosing.
Prescription compliance guaranteed.
Enhanced pet comfort.
Reduced risk of side effects.
Superior quality of care.
Elimination of drug diversion and abuse.
The pet pharmaceutical industry has historically shown itself to be recession resistant and will continue its growth as the pet population increases worldwide.
Pain stemming from bone cancer in dogs is severe and often inadequately addressed. Our first product, LS-001, is a long-acting injectable designed to manage the pain associated with this condition.
The FDA has granted us a waiver of sponsor fees to support the development of LS-001 based on the product being intended for a Minor Use in a Major Species (MUMS). This waiver will save the company over $1 million in product development costs. Other benefits include eligibility to seek MUMS grants totaling up to $500,000 and seven years of exclusive marketing rights upon FDA approval of the product.
The FDA has also accepted our Investigational New Animal Drug application to develop LS-001. The acceptance by the FDA signifies that Lifescient has provided sufficient preclinical data and safety information to justify testing in clinical trials.
Our strategy involves applying our LAI platform to develop treatments for chronic conditions across multiple species of animals. The technical feasibility has been established by developing prototypes of several medications.
Our primary focus lies in niche segments within the veterinary medicine market, targeting conditions that larger pharmaceutical companies have historically overlooked. What sets us apart is our commitment to developing products that will address the needs of both the pet and pet families, giving us a distinctive edge in the field. To our knowledge, we stand alone in the development of subdermal long-acting injectable technology specifically tailored for veterinary medicine.
Sponsor fee waivers granted under the MUMS provision will save the company more than $1,000,000 in development costs.
FDA has accepted our Investigational New Animal application for LS-001 based on the safety data that was submitted.
Established technical feasibility for several medications.
Developed several prototypes of long-acting injectable medications.
Lifescient is seeking to raise $1.6 million via this Community Round. The capital we raise from you will be used for the following:
The pet population is growing worldwide. Pets are living longer, age related and lifestyle diseases are on the rise. We are uniquely positioned to capture a huge segment of the growing global animal health market. Our products will satisfy the growing need for superior treatment options and improve the quality of life for pet families. We invite you to join us in our dedication to elevating the standard of care for our cherished pets.
